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ABSTRACT
Substance use is pervasive in the United States. With overdose deaths on the rise for the past
decade, studies have examined the detrimental effects of a range of substances. Substance use
has been shown to affect the domains of executive functioning, while diseases such as Human
Immunodeficiency Virus (HIV) and Hepatitis-C (Hep-C) have been shown to increase the
severity of these deficits when comorbid with substance use. Alzheimer’s Dementia (AD) also
affects many of the same domains of executive functioning as substance use. However, because
of the rapid degenerative nature of the disease, individuals clinically determined to have Mild
Cognitive Impairment (MCI) with a risk of progression to AD are more uniform in symptom
presentation and discerned deficits, and are therefore more feasible to examine. This study
examined whether a history of substance abuse impairs executive function in a cumulative
manner when comorbid with MCI with a clinically indicated risk of progression to AD. While
those subject to both MCI and substance use history did have the lowest scores in all of the
assessments and in each of the conditions measured, those differences were insignificant. The
hypothesis was not supported, even though the trend in scores was in the predicted trajectory.
These results and implications are discussed, while limitations and possible future research
directions are outlined.
KEYWORDS: executive function, substance use, mild cognitive impairment, dementia,
additive effects, comorbidity, Digit Span, Trail Making Test, COWAT
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INTRODUCTION
Drug Use on the Rise
There has been much focus in the last few years, particularly in the media, on the harms
and growing crisis of opioid use and dependence (Rice, 2018). While drugs like Fentanyl and
Heroin receive considerable attention, other equally dangerous substances like methamphetamine
are largely forgotten (Robles, 2018). There are, however, indications that methamphetamine use
is becoming more prominent again. The Substance Abuse and Mental Health Services
Administration (SAMHSA) released a report detailing the trends in methamphetamine use
amongst Americans. While initial methamphetamine use was on a general downward trend for
the entire decade of 2000-2010, it has either remained stable or increased for every subsequent
year (SAMHSA, 2017). In fact, just over 100,000 people tried methamphetamine for the first
time in 2010, a number that jumped to 144,000 in the year 2013 (SAMHSA, 2017).
Supplementing those numbers is a report from the Center for Disease Control and Prevention
(CDC) noting that the rate of overdose deaths involving methamphetamine tripled between 2011
and 2016 (Hedegard et al., 2018). Furthermore, arrests and seizures of methamphetamine are on
the rise across the country (Robles, 2018). According to the National Institute on Drug Abuse
(NIDA), over 5% of individuals 12 and older have tried methamphetamine in their lifetime, and
more than 1 in 10 of those individuals have used within the last year (NIDA, 2018). These
figures foreshadow the detrimental effects methamphetamine use will have on the population,
should trends continue in the same direction and magnitude that they currently are.
Methamphetamine and opioids are not the only drugs being used with detrimental effects.
Of the 135 million people aged 12 and over in the US who admitted to current alcohol use,
almost half of them report binge drinking in the past month (SAMHSA, 2017). Binge drinking is

1

defined as consumption of five or more drinks for males (and 4 or more for females) on the same
occasion (SAMHSA, 2017). Even though alcohol use trends have stayed relatively stable in the
past few years, and even declined in some aspects, the effects of alcohol abuse still costs our
nation 250 billion dollars annually (NIDA, 2018). Overdose deaths attributed to a variety of
drugs has also been on the rise in the past decade. Cocaine, Benzodiazepines, and
antidepressants overdose deaths have been driven up in large part due to their mixture with
opioids, although cases involving no other opioids have also seen an increase in recent years for
these drugs (NIDA, 2018).

Deficits Stemming from Use
Aside from the obvious life-altering legal or even deadly consequences listed above, drug
use has well documented detrimental effects on individuals. From an etiological perspective,
however, it is difficult for researchers to discern deficits associated with specific drugs, due to
the majority of abusers using more than one substance (Fernandez-Serrano et al., 2010).
Impairment in general function domains of the brain may be compounded by polysubstance use
(Fernandez-Serrano et al., 2010; Meredith et al., 2005).
NIDA (2018) notes that substances of abuse increases the amount of dopamine in the
brain. Dopamine reinforces drug-taking behavior, and this makes these substances highly
addictive. Chronic use results in an overactive dopamine system, and causes changes in
structural and functional domains of the brain (NIDA, 2018). One of the most studied domains
is executive function, which many researchers agree is detrimentally affected by substance use
(Bechara & Martin, 2004; Garcia-Fernandez, Garcia,-Rodriguez, & Secades-Villa, 2011; Henry,
Minassian, & Perry, 2010; Meredith, et al., 2005; Simon, et al., 2000; Van Holst & Schilt, 2011;
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Yucel et al., 2007). This finding has been corroborated in adolescent users of methamphetamine
as well (King et al., 2010). Executive functioning consists of multiple domains, which work
together to allow individuals to manipulate and navigate ideas, thoughts, and challenges
(Diamond, 2013). Working memory is one aspect of executive functioning consistently studied
for assessing the extent of impairments in methamphetamine users (Bechara & Martin, 2004;
Hoffman et al., 2006; Simon et al., 2000).
One of the most significant issues for researchers in this area is linking deficits to specific
drugs. As mentioned before, this stems in large part from the majority of users being
polysubstance abusers (Fernandez-Serrano et al., 2010). In a recent meta-analysis examining
drug-specific neuropsychological impairments, none of the drugs examined, except alcohol, had
more than two studies available that met criteria for ‘pure’ users of specific drugs (FernandezSerrano, Perez-Garcia, & Verdejo-Garcia, 2011). Exacerbating this is the fact that many other
drugs have been found to impair executive functioning as well (Garcia-Fernandez, GarciaRodriguez, & Secades-Villa, 2011; Pluck et al., 2012; & Woicik et al., 2009).
While the drug-specific deficits do not completely overlap one another, their collective
impairment of executive function would be identifiable on measures of general executive
functioning in neuropsychological assessments. This is the case whether the individual is a
polysubstance user or a single substance user, although Nixon (1999) notes that polysubstance
abuse may cause more adverse neuropsychological effects than single substance abuse.
Fernandez-Serrano (2011) found that even when the main drug of choice was different, most of
the impairments between groups of polysubstance users were shared.
These impairments of executive function contain many practical consequences.
Fernandez, Rodriguez, and Villa (2011) note that changes in executive functioning caused by
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drug use can affect psychosocial functioning, the course of an addiction, and even the success of
any eventual treatment. In other words, the changes of executive functioning due to substance
use have very real implications in how individuals move forward with their lives. Van der Plas
et al. (2009) also found that gender and drug of choice can contribute to the differing effects that
drug use has on executive functioning, suggesting that men and women who use substances
might experience differing effects.
In one study investigators found methamphetamine dependence was associated with a
decrease in everyday functional ability, particularly in the areas of comprehension, finance,
transportation, communication, and medication management, when compared to drug free
participants (Henry, Minassian, & Perry, 2010). A meta-analysis on a variety of drug use studies
found that all abused drugs, except cannabis, showed association with lowered inhibition (Van
Holst & Schilt, 2011). Alcohol was found to specifically affect working memory and
visuospatial abilities (Van Holst & Schilt, 2011). In a task involving delayed rewards,
methamphetamine users were also found to discount a reward that would be delayed more than
non-users (Hoffman et al., 2006). This impulsivity was correlated with memory deficits
resulting from methamphetamine use, rather than any non-drug induced psychological
impairment. The authors suggest that it was also not associated with any other drug use history
variables that were tested or measured, such as nicotine use or marijuana use (Hoffman et al.,
2006).
Many of the neurocognitive impairments that come from drug use are dependent upon
dose and duration of use, and there are many short and long term effects of using (Meredith et
al., 2005; NIDA, 2018). Although single doses of an amphetamine can actually improve
performance in several neurocognitive domains, chronic users normally experience multiple
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neurocognitive impairments (Meredith et al., 2005). Bechara and Martin (2004) identified some
of these impairments when they compared individuals that primarily used alcohol, meth, or
cocaine against non-users. They found that a number of individuals formed a sub-group who
performed as well as non-users, but the overall groups had below normal levels of performance
on both decision making and working memory measures.
Although this study sought to identify impairments shared among abusers of different
substances, the study yielded interesting results. Methamphetamine users comprised the
majority of the impaired individuals subgroup, and were more severely impaired than individuals
who abused the other substances examined (Bechara & Martin, 2004). They concluded that
these deficits were attributed to the executive process of working memory only, rather than an
impairment of short term memory processes (Bechara & Martin, 2004).
Other studies have identified impairments that are specific to certain substance users.
Opiate users appear to particularly be affected in areas of verbal fluency, and cocaine users were
found to have lower cognitive flexibility (Van Holst & Schilt, 2011). Abusers of almost every
illicit drug develop impaired verbal memory (Meredith et al., 2005). Methamphetamine users
also become impaired on tasks of perceptual speed, manipulating information, and tasks that
combine these skills with visuomotor scanning (Meredith et al., 2005).

Abstinence
Much of the research cited has focused on active substance users, but there is also a host
of research that examines what occurs in users following various periods of abstinence. Multiple
researchers have found that methamphetamine users who are abstinent actually perform more
poorly on measures of neurocognitive impairment in the initial phases of abstinence
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(Kalechstein, Newton, & Green, 2003; Meredith et al., 2005). These studies found deficits in
domains such as attention, psychomotor speed, verbal learning and memory, and executive
functioning in users that had been abstinent for a range of 5-14 days. One of the studies, by
Kalechstein, Newton, and Green (2003), focused on ensuring that these impairment levels were
properly attributed to use and abstinence of meth, and not confounding variables, such as
demographic variables, estimated premorbid IQ, or self-reported depression.
The other article, a meta-analysis, noted that scores on psychomotor and verbal memory
tasks were initially worse during early abstinence. Between 3 and 14 months of abstinence, they
suggest that a slight improvement in these scores was detected, although this change is short of
any statistical significance (Meredith et al., 2005). Even after an average of eight months of
abstinence, former users still performed significantly worse on tasks measuring working
memory. The authors suggest the decrements in these domains never significantly recover, even
after extended periods of abstinence. Similarly, one meta-analysis which consisted of studies
requiring two weeks of abstinence, found impairments involved with opiates, alcohol, meth, and
cocaine, although these studies did not compare performance to pre-abstinence values (Van
Holst & Schilt, 2011).
Data from other studies suggest that substance users exhibit less impairment after periods
of abstinence. Simon et al. (2010) found that methamphetamine users performed better on
cognitive tasks after one month of abstinence, although those results were not statistically
significant. They also found that no considerable cognitive gains were made after the first month
of abstinence, although they suggest that longer periods of abstinence may result in significant
cognitive improvement (Simon et al., 2010). Consistent with this theory that longer periods of
abstinence are associated with significant improvements in cognition, some studies have found
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that extended abstinence can facilitate a period of neuropsychological recovery. These periods
of recovery may unfold over as long as one year, and longer abstinence was associated with
greater improvement of cognitive functioning. It should be noted this finding was not
statistically significant in that time frame (Iudicello et al., 2010). Mann et al. (1999) found that
the discrepancies of neuropsychological functioning between a control group and group of
alcohol dependent individuals were lowered to non-significant levels after several weeks of
abstinence.
More research is necessary to determine the extent or even the possibility for reduction
of deficits in cognitive functioning due to substance use. Even without significant cognitive
domain improvement, longer-term abstinence has also been associated with improvement in
mood and overall emotional distress in individuals, making abstinence from drugs beneficial
across multiple aspects for individuals (Iudicello et al., 2010).

Critiques
The previous findings reported are not universally accepted and other researchers have
found conflicting results. Hart et al. (2012) claim the results from many studies on
methamphetamine use show no significant differences on the majority of cognitive tasks. In
those studies where significant differences with a comparison group have been found, results for
the substance using group still fall within the normal range of scores for age and education
demographics. Further they claim that if methamphetamine use caused deficits in the brain, then
these deficits should be immediately apparent after administration of the drug, and not only after
chronic use of it (Hart et al., 2012). For instance, Johanson et al. (2006) found
methamphetamine users performing lower than non-users on 3 of 12 tasks administered, and
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those participants still performed within normal range. They also determined that length of
abstinence was not correlated with substantial changes in neurocognitive functioning (Johanson
et al., 2006).
Other studies have found similar results. Simon et al. (2000) found methamphetamine
users to perform more poorly than control groups on some measures (word and picture recall,
Digit Symbol, Stroop Color Word Test and Trail Making Test Part B), but found no significant
differences on other tests (Shipley Hartford Vocabulary Test, The Wisconsin Card Sort Test,
FAS Verbal Fluency Test, and the Backward Digit Span Test). In a separate study the authors
argued most researchers base their results on null hypothesis statistical significance testing, but
that using effect size analysis produces a more accurate picture of any impairment, and is more
consistent with results produced by neuroimaging studies (Jovanovski, Erb, & Zakzanis, 2005).
One study found that some methamphetamine users were neuropsychologically impaired,
while others performed within the normal range of functioning (Mariana et al., 2010). This study
ensured users were free of HIV/HEP C, which are known to compound neuropsychological
deficits, and that they were similar in age of first use, total years of use, route of consumption,
and length of abstinence. They suggest that their findings are indicative of the need for more
research into individual vulnerability differences for the neurotoxic effects of methamphetamine
use (Mariana et al., 2010).

Discerning and Explaining Deficits
The majority of researchers agree, however, that “some” deficits arise from chronic
substance use. Much of the evidence for impairments in executive functioning has been
identified either by traditional neuropsychological assessments or by neuroimaging. Multiple
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studies cite the Wisconsin Card Sort Test (WCST) as the instrument for assessing impairments
(Henry, Minassian, & Perry, 2010; Meredith et al., 2005; Simon et al., 2000). Meredith et al.
(2005) noted that methamphetamine users scored more poorly than either cocaine or heroin users
on the WCST. Simon et al. (2000) however, found no significant differences between users and
a control group on either WCST scores or scores on the Shipley Hartford Vocabulary Tests, the
FAS Verbal Fluency Tests, or the backward digit span test, although they did find significant
differences on the Digit Symbol, Trail Making Part B, and Stroop Color Word Test tasks. Other
studies utilized the Trail Making Tests, Stroop Color Word Test, Digit Span tests, LetterNumber Sequencing, Peg Board Tasks, and Wechsler Matrices tasks (Kalechstein, Newton, &
Green, 2003; King et al., 2010).
As implied in the nomenclature of neuropsychology, these observed deficits have a
biological basis. NIDA (2018) notes that drugs increase the amount of dopamine in the brain
and causes damage to nerve cells. Long term use changes dopaminergic neurons, by displacing
the dopamine and reversing its transport, ultimately leading to extracellular levels of the
neurotransmitter (Johanson et al., 2006; Nordahl, Salo, & Leamon, 2003). Meredith et al.
(2005) state that poorer scores on assessments are indicative of frontal lobe dysfunction, a
sentiment echoed by other researchers for a variety of different drugs (Garavan & Hester, 2007;
Henry, Minassian, & Perry, 2010; Verdejo-Garcia et al., 2006). Other studies have identified
specific areas of the prefrontal cortex measured in assessments (dorsolateral prefrontal cortex,
orbitofrontal cortex, and the anterior cingulate cortex) and found a generalized pattern in
abnormal performance associated with all three of these domains after use (Verdejo-Garcia et al.,
2006).
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Others suggest brain abnormalities are slightly different in nature, specifically that the
frontostriatal and limbic systems are the most affected (Iudicello et al., 2010). Nordahl, Salo,
and Leamon (2003) point out that serotonin has been shown to be affected when monkeys are
injected with methamphetamine, but that there have been no neuroimaging studies on humans to
determine if they are affected in the same way. They note that neuroimaging has supported the
notion that methamphetamine use causes damage to multiple transmitter systems throughout the
brain, although no studies of this type have been conducted to determine reversibility or
permanency of damage (Nordahl, Salo, & Leamon, 2003). Meredith et al. (2005) state that the
specific biological markers of a brain impaired by substances persist into abstinence, however.
A number of studies have also utilized neuroimaging to determine deficits in individuals who
abuse alcohol (Petit et al., 2014; Tapert et al., 2001)

Combined Effects
An important aspect of substance use to consider is the occurrence of Human
Immunodeficiency Virus (HIV) and Hepatitis C (HEP-C). Both of these disorders are associated
with drug use, particularly drugs that may be administered intravenously. HEP-C is the most
common blood borne infection in the United States, with almost 3 million people being affected
(Kim, 2002; Martin-Thormeyer & Paul, 2009). More than a quarter million of those individuals
also have a co-infection with HIV (Martin-Thormeyer & Paul, 2009). Although HIV and HEP-C
are qualitatively different infections, they are identified as a group here and in other studies due
to their similarities in possible infection stemming from the same types of behaviors, and similar
detrimental effects on cognition. Drug users are more susceptible to diseases such as HIV/HEPC, in part because of risky behaviors such as needle sharing or unprotected sex (NIDA, 2018).
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Methamphetamine use, HIV, and HEP-C all affect neuropsychological functioning by damaging
the Central Nervous System and causing impairment (Letendre et al., 2005). Likewise, alcohol
abuse has been associated with an additive effect on neuropsychological impairment when
present with HIV in an individual (Rothlind et al., 2005). Use of these substances exacerbates
the effects of HIV/HEP-C by causing more damage to nerve cells than would otherwise be the
case without drug use (NIDA, 2018). Thus, HIV and HEP-C have an “added” or “synergistic”
effect on neurocognition when comorbid with each other or when either is comorbid with drug
abuse (Chang et al., 2005; Cherner et al., 2005; Martin-Thormeyer & Paul, 2009; Rothlind et al.,
2005). It is possible that this same principle is true when substances are comorbid with other
disorders/illnesses that affect executive functions.

Dementia and Aging
Alzheimer’s type dementia (AD) is characterized specifically by deficits in executive
functioning that become progressively worse over time (Robbins, Elliott, & Sahakian, 1996). At
least two cognitive domains must be impaired to be identified as such, and one of those must be
memory. The other impaired domain may be language, praxis, visual perception, attention, or
problem solving (Robbins, Elliott, & Sahakian, 1996). Many of the most common tests for
evaluating specific executive functioning deficits in aging are used to assess the same specific
deficits in substance use, namely: Trail Making Test B, Verbal Fluency Test (FAS), VFTAnimals Category, Digit Span (WAIS), Stroop Test, and the WCST (Faria, Alves, & CharchatFichman, 2015). These tests assess deficits in verbal fluency, working memory, planning, and
inhibitory control.
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AD is a rapid progression disease, with the average person living between 4 and 8 years
after diagnosis, and is by far the most common form of dementia (Alzheimer’s Association,
2018). From a treatment perspective it is imperative to recognize early symptoms and warning
signs. Because AD progression is so rapid and degenerative, the effects are particularly
devastating. Although symptoms for those affected by AD can be typical and follow a general
pattern, the quick decline and numerous areas of functioning that are affected (Stucky,
Kirkwood, & Donders, 2014) make it very difficult to compare multiple patients’ symptoms to
each other, particularly in a study such as this comparing the mean functioning of multiple
groups.
Mild cognitive impairment (MCI) is used, in part, to define the transition period between
normal aging cognitive changes and the onset of dementia (Peterson, 2003). When cognitive
changes greater than what can be attributed to normal aging are detected, but not meeting the
criteria for AD, a diagnosis of MCI is considered warranted. The diagnostic criteria include
behaviors and symptoms that must be present, as well as the absence of certain symptoms and
behaviors. In some ways the criteria for MCI are more uniform than those for AD.
Not all MCI-diagnosed patients will develop dementia, and the only way to definitively
diagnose AD is through neuropathological examination of brain tissue (Stucky, Kirkwood, &
Donders, 2014). There are, however, clinical indicators that point to the likelihood of a patient
with MCI progressing to a diagnosis of AD. The clinician treating the patient is responsible for
utilizing multiple methods to examine the symptoms and interpret the likelihood of an AD
diagnosis. This is an important distinction as when a comprehensive examination is performed, a
clinical diagnosis of AD is 85-90% accurate (Stucky, Kirkwood, & Donders, 2014).
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It may be possible for disorders that lead to deficits in executive functioning to have a
synergistic effect when comorbid with a history of drug use, just as HIV or HEP C do.
Executive functioning impairments caused by MCI with a clinical indication of AD may be
exacerbated when an individual has a history of substance abuse. While there has been
considerable research on many aspects of AD, there does not appear to be any examination of the
possible additive effects when MCI with a clinical indication of AD occurs in tandem with a
history of substance use. This is noteworthy, given the current demographics and statistics
associated with aging and dementia. AD is the sixth leading cause of death nationally and the
only one for which there is no cure. (Alzheimer’s Association, 2018). Nearly 6 million people
live with Alzheimer’s in the United States currently, a figure that is expected to triple in the next
30 years, as the number of individuals 65 and over grows to exceed 20% of the total population
(Alzheimer’s Association, 2018; Benshoff, Harrawood, & Koch, 2003). This leaves potential for
many problems, especially considering the “Baby Boomers” history with drug use (American
Addiction Centers, 2018).
If research supports evidence that substance use combined with clinically indicated MCI
interact to impair neurocognitive function, many avenues of research into early stage
interventions to slow decline could be possible. There also could be a better understanding into
risk factors for decline in individuals with a history of substance use. This serves as a basis for
the hypothesis in this study, namely that MCI patients with a history of substance use will have
significantly lower scores on measures of executive function than both of the ‘subjective
memory loss’ groups with or without substance use, as well as the MCI group without a known
history of drug use. The ‘subjective memory loss’ groups will consist of individuals who
presented with memory complaints, but did not meet the criteria for a diagnosis of MCI.

13

METHOD

Research Design
The purpose of this study was to explore in more detail the relationship of substance use
history and executive functioning impairment among individuals with Mild Cognitive
Impairment (MCI). A between-subjects design was employed, separating participants into one
of four conditions: Subjective Memory Loss without Substance Use History was used to measure
participants without the presence of either variable; Subjective Memory Loss with Substance Use
History and MCI diagnosis without Substance Use History were used to measure the influence of
either variables; and MCI diagnosis with Substance Use History measured the combined effects
of the variables. As the data used for this study were archival, random assignment was not
possible. Records from an outpatient clinic were reviewed and participants were designated to
their respective condition based on diagnosis they received and their past history of substance
abuse. Although 200 participants were initially expected for this study, only 101 former patients
were found to meet the criteria for inclusion. This study was approved by the university IRB
(see Appendix).

Participants
Data were gathered from archival files of 101 patients from a clinic located within a local
hospital. All were patients seen by one of three providers within the last seven years. Thirtyfour participants (34%) were found to meet the criteria for inclusion in the Subjective Memory
Loss without Substance Use condition; 46 (46%) were included in the MCI diagnosis without
Substance Use condition; 11 (11%) were included in the Subjective Memory Loss with
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Substance Use condition; and only 8 (8%) were found to include in the MCI diagnosis with
Substance Use condition. Data from two participants were deleted due to not meeting the age
limit parameter for this study, making a total of 99 participants with valid data. Participant ages
ranged from 56 to 89, with a mean age of 71. Fifty-six (56%) participants were male, and 43
(43%) were female. Due to the nature of the records reviewed, ethnicity and education were not
able to be determined. This information was stripped of all identifying information except age
and gender.

Materials
All test scores recorded were from a standard subjective memory complaint battery for
older adults used by the clinic. These are established instruments used on a regular basis at the
clinic as part of a comprehensive examination to determine neuropsychological functioning,
along with multiple other tests and measures. Scores are derived with a variety of methods. For
the TOPF, Digit Span, and COWAT, scores are determined by the number of items an individual
correctly identifies. The Trail Making Tests are scored by the length of time it takes to complete
them. Therefore, higher raw scores on these tests indicate worse performance. Assessment
scores for this study were standardized in order to analyze them uniformly, as well as to
eliminate any confusion with reported reverse-scored assessment outcomes.
Test of Premorbid Functioning. The Test of Premorbid Function (TOPF) is used to
assess an individual’s level of cognitive functioning and compare it with a predicted full scale
intelligence quotient (FSIQ). It is an updated version of the Wechsler Test of Adult Reading
(WTAR), which has been validated as a reliable measure for assessing cognitive functioning
(Mullen & Fouty, 2014). Functioning level is determined by the individual’s ability to correctly

15

pronounce a list of words. The predicted FSIQ is based on patient demographics such as age,
ethnicity, level of education, highest employment, and region of the country where the individual
was born. This assessment was utilized as a means to establish the similarity of premorbid
functioning among the participants. While these tests have been proven valid with a variety of
populations (Green et al., 2008; Whitney et al., 2010), they have been shown to be affected by
the severity of dementia in an individual (Oakley, 2012).
WAIS-IV Digit Span. The Digit Span subtest is part of the Wechsler Adult Intelligence
Scale-Fourth Edition (WAIS-IV), and is a portion of the Working Memory Index score, which
factors into the overall Full Scale IQ. It is administered by a clinician who recites sequences of
numbers in increasing length and, therefore, complexity. After each sequence, the test
participant attempts to repeat the numbers in the correct order. This subtest, and the entire
WAIS-IV, has been validated in numerous studies, utilizing multiple models of intelligence
(Benson, Hulac, & Kranzler, 2010; Holdnack et al., 2011).
Trail Making Tests A&B. The Trail Making Tests A&B measure different abilities
within the domain of executive functioning. The participant completes this task by drawing lines
between circled numbers, connecting them to the next successive number. In Trail Making Test
B, both numbers and letters are present, and the participant alternates between them in successive
order. The participant is scored according to number of mistakes and time to completion. These
tests have been validated as measures of executive function ability (Sanchez-Cubillo et al.,
2009).
Controlled Oral Word Association Test (COWAT). The COWAT is a test of verbal
fluency. The clinician presents a letter, and gives the participant 60 seconds to recite as many
words as they can recall that start with that letter. This is repeated three times with different
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letters (at the clinic where data were collected, FAS), and the scores totaled. This test has been
validated for executive function assessment (Ross et al., 2007).

Procedure
All of the participants were patients in the Neuropsychology office of a Midwestern
hospital receiving services from one of three providers in the last seven years. Reports and
assessment scores were kept in computer files. Researchers examined individual files to identify
participants that met eligibility criteria in one of four groups: Subjective Memory Complaints
with Substance Use, Subjective Memory Complaints without Substance Use, MCI without
Substance Use, or MCI with Substance Use. Subjective memory complaints, for the purpose of
this study, were defined as patients who presented with complaints of memory changes or loss,
but were shown through comprehensive neuropsychological examinations to have no evidence of
decline in memory or cognition.
Eligibility criteria included 56 years of age and older, a diagnosis of MCI with a clinical
indication of progression to AD (for the MCI conditions), a history of substance use (for the
substance use conditions), and no evidence of cognitive or memory decline (for the subjective
memory complaint conditions). Exclusion criteria included 55 years of age or younger, a
diagnosis of Hepatitis C or HIV, and diagnosis of a neurocognitive disorder other than MCI.
These diagnoses included Major Cognitive Impairment, MCI due to vascular or frontotemporal
etiologies, or Traumatic Brain Injury.
The demographic information and selected test scores were extracted and organized in
their respective conditions in a spreadsheet with a corresponding study I.D. The tests used were
part of a standard memory complaint battery used at the clinic for older adults, and included the
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following: Test of Premorbid Functioning, WAIS-IV Digit Span scores, Trail Making Tests A &
B, and the COWAT-Verbal Fluency Test. The latter four are tests used to measure aspects of
executive functioning. Some participants were found to be missing scores for individual tests.
These missing data were replaced with the overall mean score for that instrument. The number of
missing data points by test were: 5 from the Test of Premorbid Functioning, 1 from the Digit
Span subtest, 2 from the Trail Making A Test, 2 from the Trail Making B Test, and 1 from the
Controlled Oral Word Association Test. A one-way between subjects Analysis of Variance
(ANOVA) was performed to determine any difference between groups on the TOPF. A one-way
between subjects ANOVA was also utilized to determine statistically significant differences
between the conditions and the other assessments (Digit Span, Trail Making A&B, and
COWAT), and a Bonferroni Post Hoc analysis was conducted to identify in which conditions the
significant differences were found.
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RESULTS

Test of Premorbid Functioning
This test was analyzed as a method for determining whether the participants included in
the study were similar between all conditions, in terms of premorbid functioning. A one-way
between subjects ANOVA was conducted to compare the differences between the conditions.
No significant effects were found at the p<.05 level for all four conditions [F(3,95) = 1.15,
p=.334]. This indicates that all of the participants were similar in terms of premorbid
functioning, regardless of their designated condition.

Digit Span
A one-way between subjects ANOVA was conducted to compare the effect of substance
use in MCI patients on the Digit Span subtest for the conditions of Subjective Memory Loss
without Substance Use, Subjective Memory Loss with Substance Use, MCI diagnosis without
Substance Use, and MCI diagnosis with Substance Use conditions. A significant effect was
found at the p<.05 level for the four conditions [F(3,95) = 3.90, p=.011]. The Bonferroni Post
Hoc test indicated that the mean score for the Subjective Memory Loss without Substance Use
(M= 89.09, SD=12.81) condition was significantly different than the MCI diagnosis without
Substance Use (M=101.11, SD=13.20) condition, although neither the MCI diagnosis with
Substance Use (M=88.75, SD=13.30) or the Subjective Memory Loss without Substance Use
(M=96.32, SD=13.72) conditions differed significantly from any of the other 3 conditions (Table
1).
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Trail Making A
The ANOVA revealed no significant differences at the p<.05 level between any of the
conditions for the Trail Making A test [F(3,95) = 1.35, p=.263] (Table 1).

Trail Making B
The ANOVA revealed a significant difference between the conditions at the p<.05 level
for the Trail Making B test [F(3,95) = 2.87, p=.040]. The Bonferroni analysis revealed that the
significance was found between the MCI diagnosis with Substance Use condition (M=80.13,
SD=10.84) and the Subjective Memory Loss without Substance Use condition (M=96.62,
SD=15.26). The Subjective Memory Loss with Substance Use (M=89.91, SD=18.78) and the
MCI diagnosis without Substance Use (M=95.37, SD=15.28) conditions both had insignificantly
different mean scores compared to the other conditions (Table 1).

Controlled Oral Word Association Test
The ANOVA revealed a significant difference between the conditions at the p<.05 level for the
COWAT as well [F(3,95) = 5.32, p=.002]. The Bonferroni analysis indicated significance
between the MCI diagnosis with Substance Use condition (M=80.25, SD=13.02) and both the
MCI diagnosis without Substance Use (M=98.37, SD=13.32) and the Subjective Memory Loss
without Substance Use (M=96.79, SD=14.18) conditions. The Subjective Memory Loss with
Substance Use condition (M=88.11, SD=11.80) was not significantly different than any of the
other conditions (Table 1).
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Table 1. Mean scores for each assessment included in the study. Data are divided by the mean
score of individuals within each condition.
Mean Assessment Scores by Condition

Digit Span

Subjective
Memory Loss
without
Substance Use
96.32

Subjective
Memory Loss
with Substance
Use
89.09

Trail Making A

97.35

Trail Making B
COWAT

Assessment

MCI diagnosis
without
Substance Use

MCI diagnosis
with Substance
Use

101.11

88.75

97.96

99.16

88.63

96.618

89.91

95.37

80.13

96.79

88.11

98.37

80.25
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DISCUSSION

The initial hypothesis was that individuals in the MCI diagnosis with Substance Use
condition would have significantly lower scores on the assessments than any of the other
conditions. This would have suggested a possible combined effect on executive functioning
related to two conditions shown to impair executive functioning, Mild Cognitive Impairment and
Substance Abuse. For all of the assessments in our analysis, the MCI diagnosis with Substance
Use condition had the lowest mean score. This indicates that substance abuse history, when
comorbid with a diagnosis of MCI, appears to be related to an overall effect on executive
function. The hypothesis was only partially supported, as some differences did not meet the predetermined significance level and the associated effect sizes were small.
For the MCI diagnosis with Substance Use group, the Trail Making B test and the
COWAT scores were significantly lower than some of the other condition groups. On Trail
Making B, the Subjective Memory Loss without Substance Use condition had a much higher
score. Because the MCI diagnosis with Substance Use group had both substance use and mild
cognitive impairment while the Subjective Memory Loss without Substance Use group had
neither, this was expected. The MCI diagnosis with Substance Use condition on the COWAT
showed significance from the Subjective Memory Loss without Substance Use condition as well,
but also showed a significant difference from the MCI diagnosis without Substance Use
condition. This indicates that the addition of substance use was associated with significantly
different scores on this assessment when a diagnosis of MCI was involved.
Results from the MCI diagnosis without Substance Use and the Subjective Memory Loss
with Substance Use groups were informative. These groups were examined together because
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each condition included one of the variables of interest. In the data from all four of the
assessments, individuals with a history of substance use but no MCI diagnosis received lower
scores than those with an MCI diagnosis but no substance use history. These differences were
not significant for any of the tests except Digit Span. With a larger sample and similar results,
however, the data would suggest substance abuse was associated with significant impairment
comparable to that associated with MCI.
The Subjective Memory loss without Substance Use condition produced scores that were
atypical. Even though these participants should have exhibited the highest set of scores, since
they were the only group who were not subject to either of the impairing variables, this was only
the case for the Trail Making B test. In all of the other assessments, this score was actually
lower than the MCI diagnosis without Substance Use condition, although none of the differences
between any of the tests were significant. This indicates that the individuals without a diagnosis
of MCI actually exhibited a higher level of ‘impairment’ than those with a diagnosis of MCI,
although if this was the case, there must be other underlying conditions that were not measured
causing impairment, since they were not subject to either of the variables that we measured
which cause impairment.

Limitations
There were a number of limitations with the present study. The limited number of
individuals in the Subjective Memory Loss with Substance Use condition and MCI diagnosis
with Substance Use condition resulted in low power for the analyses. A larger sample for all the
groups would provide sufficient power for analysis. It is important to note, however, that
significant effects were found between some of the conditions examined even with low power. It
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is likely that with higher power in analysis, greater significance between the conditions would be
found.
Another potential limitation was the variability in symptomology across patients. Due to
the nature of the records reviewed, which utilized different terminology by different clinicians,
the criteria for inclusion in each condition was not as specific as would be ideal. Substance
abuse history was not documented thoroughly, only noted whether it was “significant” and the
primary drug of choice was identified. A diagnosis of MCI was also variously determined.
While all diagnoses were clinically indicative of progression risk to Alzheimer’s Dementia (AD),
they were termed in different manners, such as MCI vs. Early Alzheimer’s or MCI, likely of an
Alzheimer’s variety, among other terms. This created uncertainty about how likely each specific
diagnosis was for progression to AD. This limitation could be addressed in future studies by
utilizing consistent diagnostic and inclusion criteria.
Another limitation relates to the instruments included in the initial clinical assessment.
Although validated as measures of executive function, they each measure different sub-domains.
Those sub-domains may be differentially affected by specific substances, resulting in some
assessments sensitive to impairments some individuals experience but not others. Furthermore,
the tests included in this analysis do not provide a comprehensive assessment of executive
functioning. Future research would focus on specific domains within executive function, or the
specific impairments caused by substances, as a way to verify that they are the same ones
affected by AD, and actually exhibit a synergistic effect.
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Applications
Taking into consideration the previously mentioned limitations regarding generalizing the
results of this study, specifically with the inadequate sample size, there may be several
applications for the results. Even though the differences between the conditions were generally
not significant, the MCI diagnosis with Substance Use group did have the lowest scores for all of
the tests measured. This indicates that there may be a cumulative effect between substance use
and mild cognitive impairment on executive function deficits. Further research employing more
stringent criteria and a greater number of participants is needed, but if this trend is supported, the
implications are far reaching. With the current trend of demographics in the U.S., there may
soon be many more cases of individuals who are positive for both MCI as well as a history of
substance abuse. This could help clinicians to understand the nature of probable AD much
sooner based upon known history of the individual. Treatment could be developed in a more
individual manner, and diagnoses could be utilized with more certainty. Furthermore, more
research could be directed toward discerning specific deficits from certain substances, and help
understand how each substance affects the course of MCI diagnosis. Beyond knowing more
about the effects of both of these disorders, the knowledge gleaned from discerning any
cumulative effects could lead the way to understanding what interventions might be utilized for
reducing or repairing deficits caused by substance abuse.

Summary
Substance abuse is problematic, simply put. Overdose rates are at all-time highs. Trends
show multiple statistics on the rise associated with use and complications related to use.
Furthermore, substance use has been shown to affect certain domains within executive function.
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These impairments are exacerbated when substance abuse is comorbid with specific other
disorders that are also known to affect executive function. One disorder known to affect
executive functioning, but which has not to our knowledge been examined within the context of
substance abuse, is Alzheimer’s Dementia (AD), or Mild Cognitive Impairment with a clinically
indicated risk of progression to AD. This study sought to address that by comparing groups
subject to each of these disorders exclusively, a group subject to none of them, and a group
subject to both of them, using a variety of tests that have been validated for measuring executive
function.
These tests were compared using a between subjects one-way analysis of variance.
Although a Bonferroni post hoc analysis revealed that the condition of participants with both an
MCI diagnosis and substance use history did receive lower average scores than the other
conditions across all of the tests, most of the different condition scores between the tests were
not significant. Some of the tests had differing conditions with significance, none of them
exhibited significant differences between the MCI diagnosis with Substance Use condition and
the rest of the conditions measured. We discussed limitations, which included our small sample
size. Even so, the trend discovered may be promising, pending further research supporting the
same conclusions. We discussed applications of the findings, including better understanding and
being able to better individualize treatment for patients who have a history of substance use
when considering a diagnosis of mild cognitive impairment or Alzheimer’s Disease.
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